Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting (Details) - Schedule of financial information represents the operating results of the reportable segments

v3.22.1
Segment Reporting (Details) - Schedule of financial information represents the operating results of the reportable segments - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Apr. 30, 2022
Apr. 30, 2021
Apr. 30, 2022
Apr. 30, 2021
Clinical Services [Member]        
Segment Reporting Information [Line Items]        
Revenues $ 18,630 $ 25,018 $ 62,045 $ 70,229
Operating costs and expenses:        
Cost of revenues 11,180 12,733 34,969 37,436
Research and development 666 173 762 454
Selling, general and administrative 6,756 7,029 19,568 19,552
Legal fee expense 12 95 217 191
Total operating costs and expenses 18,614 20,030 55,516 57,633
Operating income (loss) 16 4,988 6,529 12,596
Other income (expense):        
Interest, net (2) (4) (7) (14)
Other 15 1 69 30
Foreign exchange loss    
Net income (loss) 29 4,985 6,591 12,612
Depreciation and amortization included above 430 399 1,286 1,189
Share-based compensation included in above:        
Selling, general and administrative 38 9 74 28
Cost of revenues 4 39 20 66
Total 42 48 94 94
Capital expenditures 202 1,544 795 2,425
Products [Member]        
Segment Reporting Information [Line Items]        
Revenues 7,592 7,779 24,742 22,689
Operating costs and expenses:        
Cost of revenues 4,869 4,018 14,191 11,718
Research and development 458 643 1,901 1,868
Selling, general and administrative 2,786 2,810 8,920 7,848
Legal fee expense 10 10 23 16
Total operating costs and expenses 8,123 7,481 25,035 21,450
Operating income (loss) (531) 298 (293) 1,239
Other income (expense):        
Interest, net 10 11 28 29
Other (2) 2 3 6
Foreign exchange loss (1,056) (33) (1,887) 428
Net income (loss) (1,579) 278 (2,149) 1,702
Depreciation and amortization included above 224 208 626 581
Share-based compensation included in above:        
Selling, general and administrative 1 41 2 73
Cost of revenues  
Total 1 41 2 73
Capital expenditures 572 180 1,788 378
Therapeutics [Member]        
Segment Reporting Information [Line Items]        
Revenues  
Operating costs and expenses:        
Cost of revenues  
Research and development 9 20 34 66
Selling, general and administrative 17 50
Legal fee expense  
Total operating costs and expenses 9 37 34 116
Operating income (loss) (9) (37) (34) (116)
Other income (expense):        
Interest, net  
Other  
Foreign exchange loss    
Net income (loss) (9) (37) (34) (116)
Depreciation and amortization included above  
Share-based compensation included in above:        
Selling, general and administrative  
Cost of revenues  
Total      
Capital expenditures      
Other [Member]        
Segment Reporting Information [Line Items]        
Revenues  
Operating costs and expenses:        
Cost of revenues  
Research and development  
Selling, general and administrative 1,900 2,226 8,472 5,659
Legal fee expense 712 956 4,621 3,786
Total operating costs and expenses 2,612 3,182 13,093 9,445
Operating income (loss) (2,612) (3,182) (13,093) (9,445)
Other income (expense):        
Interest, net 46 53 140 (55)
Other (729) (91) (1,283) (91)
Foreign exchange loss    
Net income (loss) (3,295) (3,220) (14,236) (9,591)
Depreciation and amortization included above 78 66 226 198
Share-based compensation included in above:        
Selling, general and administrative 119 208 961 473
Cost of revenues  
Total 119 208 961 473
Capital expenditures 82 23 520 67
Consolidated [Member]        
Segment Reporting Information [Line Items]        
Revenues 26,222 32,797 86,787 92,918
Operating costs and expenses:        
Cost of revenues 16,049 16,751 49,160 49,154
Research and development 1,133 836 2,697 2,388
Selling, general and administrative 11,442 12,082 36,960 33,109
Legal fee expense 734 1,061 4,861 3,993
Total operating costs and expenses 29,358 30,730 93,678 88,644
Operating income (loss) (3,136) 2,067 (6,891) 4,274
Other income (expense):        
Interest, net 54 60 161 (40)
Other (716) (88) (1,211) (55)
Foreign exchange loss (1,056) (33) (1,887) 428
Net income (loss) (4,854) 2,006 (9,828) 4,607
Depreciation and amortization included above 732 673 2,138 1,968
Share-based compensation included in above:        
Selling, general and administrative 158 258 1,037 574
Cost of revenues 4 39 20 66
Total 162 297 1,057 640
Capital expenditures $ 856 $ 1,747 $ 3,103 $ 2,870